+
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

The power of RNA sequencing in molecular oncology

We assessed the utility of RNA sequencing in molecular diagnostics by analyzing a large pan-cancer cohort ranging in age from infants to seniors. This technique is highly sensitive for the identification of gene alterations that can guide diagnosis and targeted therapy, and enables additional biological and clinical interpretation of findings beyond standard DNA-sequencing protocols.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Diagnostic RNA-seq.

References

  1. Liu, Y. et al. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. Nat. Commun. 14, 1739 (2023). This paper reports the prevalence of oncogenic gene fusions in pediatric cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Benayed, R. et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin. Cancer Res. 25, 4712–4722 (2019). This paper reports an enhanced ability to detect gene fusions when using RNA-seq relative to the use of DNA-seq.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Villani, A. et al. The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations. Nat. Cancer 4, 203–221 (2023). This paper reports comprehensive genomic profiling, including targeted DNA-seq, conducted on a subset of the samples we tested in our study.

    Article  CAS  PubMed  Google Scholar 

  4. Kaya, C. et al. Limitations of detecting genetic variants from the RNA sequencing data in tissue and fine-needle aspiration samples. Thyroid 31, 589–595 (2021). This paper reports that RNA-seq has reduced sensitivity for identifying SNVs.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. von Ahlfen, S. et al. Determinants of RNA quality from FFPE samples. PLoS ONE 2, e1261 (2007). This paper reports the stability of RNA in FFPE blocks, which are the most common type of pathology specimen.

    Article  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Siddaway, R. et al. Clinical utility of targeted RNA sequencing in cancer molecular diagnostics. Nat. Med. https://doi.org/10.1038/s41591-025-03848-8 (2025).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

The power of RNA sequencing in molecular oncology. Nat Med 31, 3268–3269 (2025). https://doi.org/10.1038/s41591-025-03973-4

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-025-03973-4

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载